Futura Medical PLC FUM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- GBX0.23
- Day Range
- GBX0.22–0.24
- 52-Week Range
- GBX0.18–3.21
- Bid/Ask
- GBX0.21 / GBX0.22
- Shares Outstanding
- 1.48B
- Market Cap
- GBX320.18M
- Volume/Avg
- 3M / 8M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.46
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Futura Medical PLC is engaged in the development and commercialization of sexual health products. Its product Eroxon is a treatment for erectile dysfunction (commercially available in multiple markets), Eroxon Intense (a new line extension in development) and WSD4000 which is in-development female sexual health portfolio. Geographically, the company derives the majority of its revenue from the United Kingdom and the European Union followed by USA and rest of the world.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 15
- Website
- https://www.futuramedical.com
Valuation
|
Metric
|
FUM
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.75 |
Price/Sales | 0.46 |
Price/Cash Flow | — |
Price/Earnings
FUM
Financial Strength
|
Metric
|
FUM
|
|---|---|
Quick Ratio | 1.61 |
Current Ratio | 1.61 |
Interest Coverage | — |
Quick Ratio
FUM
Profitability
|
Metric
|
FUM
|
|---|---|
Return on Assets (Normalized) | 36.74% |
Return on Equity (Normalized) | 73.53% |
Return on Invested Capital (Normalized) | 69.04% |
Return on Assets
FUM
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|>Qz!&p? | LOCK|>BV$& | $123B | |||
| Moderna Inc
MRNA
| LOCK|x#s$>D | LOCK|tr | $86B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|$h#YQ?# | LOCK|<b%s | $78B | |||
| argenx SE ADR
ARGX
| LOCK|!hcPBS | LOCK|?x | $50B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|pwd&T&y | LOCK|?! | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|$cqPGMV | LOCK|zjXRS | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|Lrtm$YX# | LOCK|B?$#w | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|k&@?>$% | LOCK|N%Q | $22B | |||
| Incyte Corp
INCY
| LOCK|XRd%j< | LOCK|Tt# | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|?%@BmR$ | LOCK|bS | $14B |
United States